Bright Minds Biosciences Inc reports a Return on Equity (ROE) of -8.93%.

What is DRUG's dividend yield?

Bright Minds Biosciences Inc offers a dividend yield of 0.00%.

What is DRUG's Quality Score?

Our AI rates DRUG's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy DRUG?

Our AI Timing Score for DRUG is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does DRUG belong to?

Bright Minds Biosciences Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Bright Minds Biosciences Inc (DRUG) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

DRUG AI Analysis Summary

Our AI summary for DRUG: Bright Minds Biosciences Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -8.93%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

DRUG

Bright Minds Biosciences Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 77.35

3.57 (4.84%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-8.9%

ROE

-8.8%

ROA

0.00%

Div Yield

BRIGHT MINDS BIOSCIENCES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 77.35 Price 3.57 (4.84%) Day Change	NEWS SCORE: 89

DRUG, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	77.35
PBV / Sector	2.35 / 44,022.72
Earning Per Share	-2.94

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	17.93 M GREAT
Average 1W Daily Value	15.65 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-8.82 / 185,260.96
ROA Average (%) / Sector	-60.04 / 36,684.70
ROA Change Average (%) / Sector	-44.54 / 422,221.66
ROE (%) / Sector	-8.93 / 243,762.23
ROE Average (%) / Sector	-65.62 / 48,758.47
ROE Change Average (%) / Sector	-46.66 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:06
Symbol	DRUG
Name	BRIGHT MINDS BIOSCIENCES INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	9.81 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	723.93 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 19 Vestry Street, New York, NY, United States, 10013

Phone: 647 865 8622

Website: https://brightmindsbio.com

Sector: Healthcare >> Biotechnology

Description: Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.